Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
Non-Hodgkin's Lymphoma
DRUG: rituximab
To determine whether treatment with rituximab causes a clinically significant effect on immunological recall response to tetanus vaccine in NHL patients, 8.5 months after treatment
To determine whether NHL patients can mount a primary response to KLH after treatment with rituximab, 8.5 months after treatment|To determine whether NHL subjects treated with rituximab experience clinically significant changes in antibody titers to a panel of specific antigens, 8.5 months after treatment
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.